

Supplemental Table I. Characteristics of the patients.

	Non infected patients n=21	Infected patients n=20	p
Age, median [IQR] (years)	59 [47.00-68.00]	59 [54.75-64.25]	0.804
Female, n (%)	17 (81.0)	17 (85.0)	1.000
Current inflammatory disease			
Rheumatoid arthritis, n (%)	20 (95.2)	19 (95.0)	1.000
Anti-Citrullinated Protein Antibodies, n (%)	17 (85.0)	16 (80.0)	1.000
Rheumatoid factor, n (%)	13 (68.4)	14 (77.8)	0.714
Current DAS28, median [IQR]	2.90 [2.01-3.26]	2.62 [1.76-3.23]	0.540
Juvenile idiopathic arthritis, n (%)	1 (4.8)	1 (5.0)	1.000
Tocilizumab treatment			
Intravenous, n (%)	15 (71.4)	19 (95.0)	0.093
Subcutaneous, n (%)	6 (28.6)	1 (5.0)	0.093
Duration, median [IQR] (days)	1215.00 [380.00-1474.00]	402.00 [93.75-1017.75]	0.120
Previous biological therapeutics, n (%)	17 (81.0)	17 (85.0)	1.000
Current treatments			
GCs, n (%)	10 (47.6)	12 (60.0)	0.536
Dosage, median [IQR] (mg/day)	5.00 [5.00-9.75]	6.00 [4.75-10.00]	0.866
Duration, median [IQR] (days)	45.00 [41.00-136.00]	24.00 [5.00-116.00]	0.515
Methotrexate, n (%)	13 (61.9)	9 (45.0)	0.354
Dosage, median [IQR] (mg/day)	12.50 [10.00-15.00]	15.00 [10.00-15.00]	0.890
Duration, median [IQR] (days)	57.50 [29.50-102.50]	72.00 [48.00-156.00]	0.269
Symptoms, n (%)	21 (100.0)	20 (100.0)	
Fever, n (%)	1 (4.8)	12 (60.0)	<0.001
Laboratory features at admission			
EC, median [IQR] (G/l)	0.20 [0.11-0.29]	0.06 [0.01-0.16]	0.010
NC, median [IQR] (G/l)	3.90 [2.27-6.90]	7.43 [5.46-9.48]	0.020
LC, median [IQR] (G/l)	1.84 [1.35-2.30]	1.40 [0.97-1.64]	0.014
CRP, median [IQR] (mg/L)	0.65 [0.30-1.58]	3.00 [1.05-120.30]	0.008
Fibrinogen, median [IQR] (g/L)	2.67 [2.20-3.05]	2.50 [2.31-5.32]	0.600
EC/NCx1000, median [IQR]	48.50 [27.50-76.70]	6.54 [1.33-30.60]	<0.010

Values are the number (%) of patients for categorical variables, and the median [Q1-Q3] for continuous variables. IQR: interquartile range. DAS: Disease Activity Score. GCs: glucocorticoids. CRP: C-Reactive Protein. EC: Eosinophil Count. NC: Neutrophil Count. LC: Lymphocyte Count.